Søren S. Lund

3.3k total citations
50 papers, 1.9k citations indexed

About

Søren S. Lund is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Søren S. Lund has authored 50 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 44 papers in Endocrinology, Diabetes and Metabolism, 22 papers in Molecular Biology and 20 papers in Surgery. Recurrent topics in Søren S. Lund's work include Diabetes Treatment and Management (35 papers), Metabolism, Diabetes, and Cancer (21 papers) and Pancreatic function and diabetes (18 papers). Søren S. Lund is often cited by papers focused on Diabetes Treatment and Management (35 papers), Metabolism, Diabetes, and Cancer (21 papers) and Pancreatic function and diabetes (18 papers). Søren S. Lund collaborates with scholars based in Germany, Denmark and United States. Søren S. Lund's co-authors include Allan Vaag, Uli C. Broedl, Bianca Hemmingsen, Jørn Wetterslev, Christian Gluud, Thomas Almdal, Hans J. Woerle, Odd Erik Johansen, David Z.I. Cherney and Mark E. Cooper and has published in prestigious journals such as Circulation, PLoS ONE and Diabetes.

In The Last Decade

Søren S. Lund

45 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Søren S. Lund Germany 22 1.5k 659 635 245 242 50 1.9k
Carolina Solis‐Herrera United States 18 1.3k 0.9× 791 1.2× 828 1.3× 259 1.1× 195 0.8× 38 1.7k
Fady T. Botros United States 18 1.1k 0.7× 704 1.1× 358 0.6× 122 0.5× 339 1.4× 40 1.6k
Anna Maria Langkilde Sweden 15 1.9k 1.3× 1.0k 1.6× 901 1.4× 158 0.6× 115 0.5× 21 2.1k
Cecilia C. Low Wang United States 14 866 0.6× 430 0.7× 443 0.7× 253 1.0× 457 1.9× 39 1.8k
Patrick Sheridan Canada 12 1.0k 0.7× 628 1.0× 303 0.5× 261 1.1× 282 1.2× 13 1.8k
Lennart Tonneijck Netherlands 23 1.9k 1.3× 641 1.0× 844 1.3× 264 1.1× 307 1.3× 40 2.6k
Mikaela Sjöstrand Sweden 22 1.1k 0.8× 452 0.7× 451 0.7× 295 1.2× 824 3.4× 49 1.9k
Eleni Athanasiadou Greece 14 1.3k 0.9× 467 0.7× 625 1.0× 116 0.5× 91 0.4× 21 1.6k
R. S. Elkeles United Kingdom 23 881 0.6× 503 0.8× 589 0.9× 236 1.0× 481 2.0× 72 1.9k
F. Travert France 12 1.2k 0.9× 347 0.5× 341 0.5× 157 0.6× 366 1.5× 20 1.7k

Countries citing papers authored by Søren S. Lund

Since Specialization
Citations

This map shows the geographic impact of Søren S. Lund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Søren S. Lund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Søren S. Lund more than expected).

Fields of papers citing papers by Søren S. Lund

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Søren S. Lund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Søren S. Lund. The network helps show where Søren S. Lund may publish in the future.

Co-authorship network of co-authors of Søren S. Lund

This figure shows the co-authorship network connecting the top 25 collaborators of Søren S. Lund. A scholar is included among the top collaborators of Søren S. Lund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Søren S. Lund. Søren S. Lund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Rosenstock, Julio, Ahmed A. Kolkailah, Darren K. McGuire, et al.. (2023). Incident and recurrent hypoglycaemia with linagliptin and glimepiride over a median of 6 years in the CAROLINA cardiovascular outcome trial. Diabetes Obesity and Metabolism. 25(6). 1453–1463.
3.
Almdal, Thomas, Peter Vestergaard, Louise Lundby‐Christensen, et al.. (2021). Effect of metformin and insulin vs. placebo and insulin on whole body composition in overweight patients with type 2 diabetes: a randomized placebo-controlled trial. Osteoporosis International. 32(9). 1837–1848. 10 indexed citations
4.
Larsen, Emil List, Louise Lundby‐Christensen, Trine Welløv Boesgaard, et al.. (2021). Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial. Free Radical Biology and Medicine. 178. 18–25. 1 indexed citations
5.
6.
Almdal, Thomas, Peter Vestergaard, Louise Lundby‐Christensen, et al.. (2020). Effect of Metformin vs. Placebo in Combination with Insulin Analogues on Bone Markers P1NP and CTX in Patients with Type 2 Diabetes Mellitus. Calcified Tissue International. 107(2). 160–169. 10 indexed citations
7.
Thorsteinsson, Birger, Niels Wiinberg, Andreas Kryger Jensen, et al.. (2020). Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes. Journal of Diabetes and its Complications. 34(10). 107681–107681.
8.
McGuire, Darren K., Bernard Zinman, Silvio E. Inzucchi, et al.. (2020). Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. The Lancet Diabetes & Endocrinology. 8(12). 949–959. 50 indexed citations
9.
Inzucchi, Silvio E., Bernard Zinman, Christoph Wanner, et al.. (2020). 131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. Diabetes. 69(Supplement_1). 1 indexed citations
10.
Almdal, Thomas, Peter Vestergaard, Louise Lundby‐Christensen, et al.. (2018). The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial. Osteoporosis International. 29(11). 2517–2526. 25 indexed citations
11.
12.
Cherney, David Z.I., Mark E. Cooper, Ilkka Tikkanen, et al.. (2017). Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney International. 93(1). 231–244. 181 indexed citations
13.
Jordan, Jens, Jens Tank, Karsten Heusser, et al.. (2017). The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus. Journal of the American Society of Hypertension. 11(9). 604–612. 78 indexed citations
14.
Cherney, David Z.I., Søren S. Lund, Bruce A. Perkins, et al.. (2016). The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 59(9). 1860–1870. 148 indexed citations
15.
Hemmingsen, Bianca, Jørn Wetterslev, Allan Vaag, et al.. (2012). Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ. 344(apr19 1). e1771–e1771. 72 indexed citations
16.
Engelen, Lian, Søren S. Lund, Isabel Ferreira, et al.. (2011). Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes. European Journal of Endocrinology. 164(3). 371–379. 17 indexed citations
17.
Hemmingsen, Bianca, Søren S. Lund, Christian Gluud, et al.. (2011). Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 343(nov24 1). d6898–d6898. 263 indexed citations
18.
Lund, Søren S., Lise Tarnow, Anne Sofie Astrup, et al.. (2009). Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obesity and Metabolism. 11(10). 966–977. 41 indexed citations
19.
Lund, Søren S., M B Petersen, M. Frandsen, et al.. (2008). Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type‐2 diabetes mellitus. Scandinavian Journal of Clinical and Laboratory Investigation. 68(7). 628–640. 10 indexed citations
20.
Lund, Søren S., Lise Tarnow, Coen D.A. Stehouwer, et al.. (2007). Targeting hyperglycaemia with either metformin or repaglinide in non‐obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes Obesity and Metabolism. 9(3). 394–407. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carolina Solis‐Herrera Breakdown of academic impact, for papers by Fady T. Botros Breakdown of academic impact, for papers by Anna Maria Langkilde Breakdown of academic impact, for papers by Cecilia C. Low Wang Breakdown of academic impact, for papers by Patrick Sheridan Breakdown of academic impact, for papers by Lennart Tonneijck Breakdown of academic impact, for papers by Mikaela Sjöstrand Breakdown of academic impact, for papers by Eleni Athanasiadou Breakdown of academic impact, for papers by R. S. Elkeles Breakdown of academic impact, for papers by F. Travert
Rankless by CCL
2026